MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Last trade$6.53
Day change-$0.37 (-5.36%)
Day range$6.47 – $7.35
Volume297,978
Market cap$383M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$383.47M
Price / earnings
—
Price / book
1.1×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.29×
Profitability
Earnings per share
-$4.14
Return on assets
-62.39%
Return on equity
-65.99%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
16.52×
Quick ratio
16.52×
Cash ratio
3.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$177.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MPLT, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$10.11M
$10.82M
$18.75M
Research and development
$53.44M
$53.68M
$64.62M
Total operating expenses
$63.55M
$64.5M
$83.38M
Operating income
-$63.55M
-$64.5M
-$83.38M
Interest expense
$0
$0
$0
Income before taxes
-$60.19M
-$60.67M
-$79.55M
Income taxes
$0
$0
$0
Net income
-$60.19M
-$60.67M
-$79.55M
Net income attributable to common shareholders
-$60.19M
-$60.67M
-$79.55M
EBITDA
-$63.4M
-$64.34M
-$83.24M
Basic earnings per share
-$1.32
-$1.34
-$2.45
Diluted earnings per share
-$1.32
-$1.34
-$2.45
Recent news
Company coverage with links to the original publishers.
MapLight Therapeutics' CFO Setia Vishwas sold 36,371 shares worth approximately $1.02 million in May 2026 through a pre-arranged Rule 10b5-1 trading plan. The sale reduced his direct holdings by 9.3%, though he retains 356,256 shares. The article notes this shouldn't be interpreted as a lack of confidence since it was part of a predetermined trading plan. MapLight, a clinical-stage biotech company focused on CNS disorders, has seen its stock gain 70.8% over the past year but continues to report deepening losses as it advances its pipeline.
MapLight Therapeutics announced that its Phase 2 ZEPHYR trial for ML-007C-MA (schizophrenia treatment) and Phase 2 IRIS trial for ML-004 (autism spectrum disorder) are progressing ahead of schedule, with topline results now expected in Q3 2026. The company cited accelerated enrollment pace and disciplined execution as drivers of the timeline acceleration.
MapLight Therapeutics completed its initial public offering of 16,962,500 shares at $17.00 per share, raising $296.3 million. The company is a clinical-stage biopharmaceutical firm focused on central nervous system disorders, with a lead product candidate ML-007C-MA for schizophrenia and Alzheimer's disease psychosis.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.